Grundmann R, Wienand P, Runde A, Baldamus C A, Arns W, Burkhardt U
Dtsch Med Wochenschr. 1987 May 22;112(21):827-31. doi: 10.1055/s-2008-1068148.
The effectiveness of preventing cytomegalovirus (CMV) infections by administering CMV hyperimmunoglobulin was evaluated in a prospective randomized trial. The patients in the treatment group (n = 50) had intravenous infusions of 2 ml/kg bodyweight of CMV-Polyglobin at three-week intervals, up to day 105 after kidney transplantation. The 50 patients in the control group received no infusions. There was no significant difference between the treatment and control groups in transplant survival or patients survival rates. But the number of symptomatic CMV infections was higher in the control (n = 11) than the treatment group (n = 5). There were also significantly fewer symptomatic herpes-simplex infections in the treatment (n = 6) than in the control group (n = 25). It is concluded from these results that prophylaxis with CMV hyperimmunoglobulin should be undertaken either selectively or for shorter periods than those chosen for the reported trial.
在一项前瞻性随机试验中评估了通过给予巨细胞病毒（CMV）高免疫球蛋白预防CMV感染的有效性。治疗组（n = 50）的患者在肾移植后每隔三周静脉输注2 ml/kg体重的CMV多球蛋白，直至第105天。对照组的50名患者未接受输注。治疗组和对照组在移植存活率或患者存活率方面无显著差异。但对照组有症状的CMV感染数量（n = 11）高于治疗组（n = 5）。治疗组有症状的单纯疱疹感染（n = 6）也明显少于对照组（n = 25）。从这些结果得出结论，CMV高免疫球蛋白的预防应选择性进行或疗程应短于所报道试验中所选用的疗程。
